Homologous Recombination Deficiency clinical trials at UCSF

1 research study open to eligible people

Showing trials for

  • Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

    open to eligible people ages 18 years and up

    This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients with homologous recombinant deficient solid tumors.

    San Francisco, California and other locations

Our lead scientists for Homologous Recombination Deficiency research studies include .

Last updated: